Literature DB >> 21822549

Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan.

Yuichi Hosokawa1, Takahiro Kinoshita, Masaru Konishi, Shinichiro Takahashi, Naoto Gotohda, Yuichiro Kato, Hiroyuki Daiko, Mitsuyo Nishimura, Kenji Katsumata, Yasuyuki Sugiyama, Taira Kinoshita.   

Abstract

BACKGROUND: Treatment strategy for adenocarcinoma of the esophagogastric junction (AEG) remains controversial. The aims of this study are to evaluate results of surgery for AEG, to clarify clinicopathological differences according to the Siewert classification, and to define prognostic factors.
METHODS: We retrospectively analyzed 179 consecutive patients with Siewert type I, II, and III AEG who underwent curative (R0) resection at the National Cancer Center Hospital East between January 1993 and December 2008.
RESULTS: Patients with AEG were divided according to tumor: 10 type I (5.6%), 107 type II (59.8%), and 62 type III (34.6%). Larger, deeper tumors and nodal metastasis were more common in type III than type II tumors. No significant differences were seen in 5-year survival rates among the three types: type I (51.4%), type II (51.8%), and type III (62.6%). Multivariate analysis showed that depth of tumor and mediastinal lymph node metastasis were independent prognostic indicators. The recurrence rate for patients with mediastinal lymph node metastasis was 87.5%. The risk factors for mediastinal lymph node metastasis were length of esophageal invasion and histopathological grade.
CONCLUSIONS: Mediastinal lymph node metastasis and tumor depth were significant and independent factors for poor prognosis after R0 resection for AEG. Esophageal invasion and histopathological grade were significant and independent factors for mediastinal lymph node metastasis.

Entities:  

Mesh:

Year:  2011        PMID: 21822549     DOI: 10.1245/s10434-011-1983-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  56 in total

Review 1.  Overview of multimodal therapy for adenocarcinoma of the esophagogastric junction.

Authors:  Kei Hosoda; Keishi Yamashita; Natusya Katada; Masahiko Watanabe
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-08-01

2.  Pattern of abdominal nodal spread and optimal abdominal lymphadenectomy for advanced Siewert type II adenocarcinoma of the cardia: results of a multicenter study.

Authors:  Kazumasa Fujitani; Isao Miyashiro; Shoki Mikata; Shigeyuki Tamura; Hiroshi Imamura; Johji Hara; Yukinori Kurokawa; Jyunya Fujita; Kazuhiro Nishikawa; Yutaka Kimura; Shuji Takiguchi; Masaki Mori; Yuichiro Doki
Journal:  Gastric Cancer       Date:  2012-08-16       Impact factor: 7.370

3.  Comparison of the clinicopathological characteristics and the survival outcomes between the Siewert type II/III adenocarcinomas.

Authors:  Wei-Han Zhang; Xin-Zu Chen; Kai Liu; Kumar Anil; Kun Yang; Jia-Ping Chen; Zong-Guang Zhou; Jian-Kun Hu
Journal:  Med Oncol       Date:  2014-07-15       Impact factor: 3.064

4.  Laparoscopic-assisted versus open total gastrectomy for Siewert type II and III esophagogastric junction carcinoma: a propensity score-matched case-control study.

Authors:  Chang-Ming Huang; Chen-Bin Lv; Jian-Xian Lin; Qi-Yue Chen; Chao-Hui Zheng; Ping Li; Jian-Wei Xie; Jia-Bin Wang; Jun Lu; Long-Long Cao; Mi Lin; Ru-Hong Tu
Journal:  Surg Endosc       Date:  2016-12-15       Impact factor: 4.584

5.  Value of splenectomy in patients with Siewert type II adenocarcinoma of the esophagogastric junction.

Authors:  Hironobu Goto; Masanori Tokunaga; Norihiko Sugisawa; Yutaka Tanizawa; Etsuro Bando; Taiichi Kawamura; Masahiro Niihara; Yasuhiro Tsubosa; Masanori Terashima
Journal:  Gastric Cancer       Date:  2012-11-18       Impact factor: 7.370

6.  Clinicopathological Characteristics and Prognostic Factors of Patients with Siewert Type II Esophagogastric Junction Carcinoma: A Retrospective Multicenter Study.

Authors:  Tatsuo Matsuda; Yukinori Kurokawa; Takaki Yoshikawa; Kentaro Kishi; Kazunari Misawa; Masaki Ohi; Shinji Mine; Naoki Hiki; Hiroya Takeuchi
Journal:  World J Surg       Date:  2016-07       Impact factor: 3.352

7.  Adenocarcinoma of esophagogastric junction: controversial classification, surgical management, and clinicopathology.

Authors:  Lei Huang; A-Man Xu
Journal:  Chin J Cancer Res       Date:  2014-06       Impact factor: 5.087

8.  Lymph node metastasis and lymphadenectomy of resectable adenocarcinoma of the esophagogastric junction.

Authors:  Xin-Zu Chen; Wei-Han Zhang; Jian-Kun Hu
Journal:  Chin J Cancer Res       Date:  2014-06       Impact factor: 5.087

9.  Adenocarcinoma of esophagogastric junction.

Authors:  Jing-Yu Deng; Han Liang
Journal:  Chin J Cancer Res       Date:  2014-08       Impact factor: 5.087

10.  Optimal surgical management for esophagogastric junction carcinoma.

Authors:  Tatsuo Matsuda; Hiroya Takeuchi; Shinichi Tsuwano; Rieko Nakamura; Tsunehiro Takahashi; Norihito Wada; Hirofumi Kawakubo; Yoshiro Saikawa; Tai Omori; Yuko Kitagawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.